Cargando…

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

BACKGROUND: This study investigated the potential clinical utility of circulating free DNA (cfDNA) as a source of BRAF mutation detection in patients enrolled into a phase II study of AZD6244, a specific MEK1/2 inhibitor, in patients with advanced melanoma. METHODS: BRAF mutations were detected usin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Board, R E, Ellison, G, Orr, M C M, Kemsley, K R, McWalter, G, Blockley, L Y, Dearden, S P, Morris, C, Ranson, M, Cantarini, M V, Dive, C, Hughes, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778539/ https://www.ncbi.nlm.nih.gov/pubmed/19861964 http://dx.doi.org/10.1038/sj.bjc.6605371

Ejemplares similares

(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors
por: Desar, Ingrid M. E., et al.
Publicado: (2012)

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
por: Beloueche-Babari, M, et al.
Publicado: (2013)

Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
por: Gao, Jin-Hang, et al.
Publicado: (2015)

Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
por: Gao, Jin-Hang, et al.
Publicado: (2022)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
por: Carvajal, Richard D., et al.
Publicado: (2015)

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2018)

Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2022)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
por: Leijen, Suzanne, et al.
Publicado: (2011)

Resistance to Selumetinib (AZD6244) in Colorectal Cancer Cell Lines is Mediated by p70S6K and RPS6 Activation()
por: Grasso, Silvina, et al.
Publicado: (2014)

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer
por: Greystoke, A, et al.
Publicado: (2012)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
por: Greystoke, A, et al.
Publicado: (2011)

A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
por: Khoja, L, et al.
Publicado: (2012)

Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation
por: Zhang, Qin, et al.
Publicado: (2018)

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
por: Yokota, T, et al.
Publicado: (2011)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity
por: Whipple, C A, et al.
Publicado: (2014)

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
por: Heinzerling, L, et al.
Publicado: (2013)

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
por: Zuidervaart, W, et al.
Publicado: (2005)

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression
por: Lin, J, et al.
Publicado: (2011)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
por: Sakaizawa, K, et al.
Publicado: (2012)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells
por: Kim, Ki Hyung, et al.
Publicado: (2009)

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
por: Qu, Yiqing, et al.
Publicado: (2014)

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
por: Saridaki, Z, et al.
Publicado: (2010)

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
por: Brookes, K, et al.
Publicado: (2010)

Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study
por: MacRae, Calum A., et al.
Publicado: (2022)

Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients
por: Rawson, J B, et al.
Publicado: (2011)

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
por: van Grieken, N C T, et al.
Publicado: (2013)

Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients
por: Stovold, R, et al.
Publicado: (2013)

BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival
por: Hugdahl, Emilia, et al.
Publicado: (2016)

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
por: Dive, C, et al.
Publicado: (2010)

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples
por: Ellison, Gillian, et al.
Publicado: (2010)

Clinical predictors of 2-year outcome of resective epilepsy surgery in adults with refractory epilepsy: a cohort study
por: Kanchanatawan, B, et al.
Publicado: (2014)

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
por: Wilson, G R, et al.
Publicado: (2006)

Improving the clinical interpretation of missense variants in X linked genes using structural analysis
por: Sallah, Shalaw Rassul, et al.
Publicado: (2022)

Diagnostic accuracy of history taking, physical examination and imaging for non-chronic finger, hand and wrist ligament and tendon injuries: a systematic review update
por: Krastman, Patrick, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g7obucl0qu0pga7nkgk1auv2kd